Joseph A Odin, MD, PhD
- ASSOCIATE PROFESSOR | Medicine, Liver Diseases
Specialties:Liver Medicine, Liver Transplantation
Dr. Odin is an associate professor in the Division of Liver Diseases and the Recanati/Miller Transplantation Institute with a clinical background in gastroenterology and liver disease. He is co-director of the Mount Sinai Autoimmune Liver Disease Program. He has research interest in liver autoimmunity and toxicology. His current research studies are focused on novel treatments for primary biliary cirrhosis, primary sclerosing cholangitis and the effect of drugs and toxins on the liver. He cares for individuals with all liver diseases including those with liver transplants. His research is supported by the NIH and he has received past support and awards from the American Gastroenterolofical Association and the American Association for the Study of Liver Disease. He also receives support from pharmaceutical companies for participation in clinical trials examining treatments for viral hepatitis.
Dr. Odin was recently designated as a Fellow of the American Association for the Study of Liver Diseases (FAASLD) — the highest honor among AASLD membership categories — which recognizes superior professional achievement in clinical or academic practice, and in basic or clinical research.
RMTI Website: www.MountSinaiRMTI.org
Autoimmune Liver Disease Treatment Program
- Endoscopic Band Ligation
- Esophageal Varices
- Hepatitis A
- Hepatitis B
AB, Cornell University
MD, Mount Sinai Sch. of Medicine CUNY
Residency, Internal Medicine, Mount Sinai Hospital
Fellowship, Gastroenterology, Johns Hopkins Hospital
Solomon Silver Award for Clinical Research
Research Excellence in GI and Liver Disease Award
Dr. Odin's liver research focuses on Autoimmune Liver Disease, Toxicity, Fatty Liver Disease, and Viral Hepatitis. Clinical trials and studies are being conducted or planned for primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, drug or toxin induced liver injury, hepatitis B and C, and non-alcoholic fatty liver disease. Some of the research is investigator initiated while other studies are supported by the National Institutes of Health or Pharmaceutical Companies.
- Genomics of Primary Biliary Cirrhosis
The purpose of this study is to investigate whether genes (the inherited genetic material passed from parents to their children) make people more likely to develop Primary Bilary Cirrhosis (PBC).
Discovery of these proposed genes will help us to better understand how...
- A 12-week, double-blind, randomized, placebo-controlled, Phase 2 study, to evaluate the effects of two doses of MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC) and an inadequate response to ursodeoxycholic acid (UDCA)
The purpose of this study is to compare the effectiveness and safety of MBX-8025 on Primary Biliary Cirrhosis (PBC) when available treatment with UDCA has proved inadequate. This will be assessed by looking at how the drug affects PBC.
Subjects may quali...
- A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)
This is a Phase 2b dose ranging randomized double blind placebo controlled trial designed to assess the efficacy and safety of simtuzumab in subjects with Primary Sclerosing Cholangitis (PSC). The study drug named simtuzumab (also known as GS6624) is considered investigational...
- A randomized double-blind controlled evaluation of tenofovir DF versus adefovir dipivoxil for the treatment of presumed pre-core mutant chronic hepatitis B
The purpose of this study is to compare the safety and the effectiveness of tenofovir DF (TDF) to that of adefovir dipivoxil (ADV) in patients chronically infected with hepatitis B (HBV). TDF is approved for the treatment of HIV infection in the United States, Australia, and E...
Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, Xu C, Lu Y, Chen W, Juran BD, Coltescu C, Mason AL, Milkiewicz P, Myers RP, Odin JA, Luketic VA, Speiciene D, Vincent C, Levy C, Gregersen PK, Zhang J, Heathcote EJ, Lazaridis KN, Amos CI, Siminovitch KA. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nature genetics 2010 Aug; 42(8).
Singal AK, Stanca CM, Clark V, Dixon L, Levy C, Odin JA, Fiel MI, Friedman SL, Bach N. Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature. Hepatology international 2011 Sep; 5(3).
Allina J, Grabowski J, Doherty-Lyons S, Fiel MI, Jackson CE, Zelikoff JT, Odin JA. Maternal allergy acts synergistically with cigarette smoke exposure during pregnancy to induce hepatic fibrosis in adult male offspring. Journal of immunotoxicology; 8(4).
Hirschfield GM, Xie G, Lu E, Sun Y, Juran BD, Chellappa V, Coltescu C, Mason AL, Milkiewic